March 1-3, the 3rd National TB Innovation Forum hosted by Innovation Alliance on Tuberculosis Diagnosis and Treatment（Beijing）（IATB）was held in the beautiful coastal city of Xiamen.
“Internationalization” is the biggest characteristic of this Innovation Forum. The conference invited many international partners, established an international platform for exchanging advanced experience and technology domestic and overseas, and convey China's voice to the world.
BaSO Group, as a professional research and development enterprise of tuberculosis diagnosis and treatment products in China, was invited to participate in the event once again. And for the first time, the self-developed second-generation Fully Automatic Mycobacterium Culture Monitor (Model:BS-1224) was exhibited. The larger throughput detection platform, the more scientific and technological design, and the more user-friendly control interface made the delegates stop and visit and appreciate it.
The parallel "International Forum on TB R&D Cooperation" and the first "Seminar on Global TB Public Market Access and Development Overseas Opportunities for China’ Indigenous Diagnostic Companies" were attended by the World Health Organization (WHO), the Global Health Lab, Medecins Sans Frontieres (MSF), the Global Alliance for TB Drug Development, the Stop TB Partnership, and Bill & Melinda Gates Foundation Experts and scholars from international organizations, together with Chinese TB product R&D companies and scholars in professional fields, shared and exchanged research and development progress and application experience on TB diagnosis, new drugs and treatment schemes, artificial intelligence image-assisted diagnosis.
As Professor Li Liang, chairman of the IATB and vice president of Beijing Chest Hospital, said in his opening speech of the "OverSeas Seminar”, We are in the transition from using international brands to creating value for the international market. This is also the original intention of the National TB Innovation Forum to organize the "International Forum" and "Enterprise going to the sea seminar".
The technical officer from the World Health Organization's China Office, a commissioner from the Clinton Health Development Organization (CHAI) in the United States, and the head of the international Department of Sinophelic International Group discussed how Chinese companies can go abroad and participate in the international procurement of public TB medical and health products. How to use the national resources and professional platforms to show the world their own research and development capabilities and intellectual manufacturing strength and so on.
BaSO will continue to look to the world, rely on professional platforms, learn from successful experiences, and join hands with industry peers to deliver excellent medical products made in China to more international markets in need, help China's tuberculosis diagnosis and treatment products to the world, and contribute to the realization of global tuberculosis prevention and control goals.
